NCT04313868View on ClinicalTrials.gov

GEN2 Directed Cancer Immunotherapy Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 13, 2014

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions
Hepatocellular CarcinomaMetastatic Cancer
Interventions
DRUG

GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Trial Locations (4)

1101

National Kidney and Transplant Institute, Quezon City

1112

St. Luke's Medical Center, Quezon City

1229

Makati Medical Center, Makati City

Unknown

The Medical City, Pasig

Sponsors

Lead Sponsor

GenVivo, Inc.
All Listed Sponsors
lead

GenVivo, Inc.

INDUSTRY

NCT04313868 - GEN2 Directed Cancer Immunotherapy Trial | Biotech Hunter | Biotech Hunter